NASDAQ: GILD) has released detailed 48-week results from a Phase 3 study evaluating the efficacy and safety of switching from a regimen containing abacavir
, dolutegravir, and lamivudine (600/50/300mg) (ABC/DTG/3TC) to Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg), a once-daily single tablet regimen, in virologically suppressed adults with HIV, the company said.
Supply of medicines: Abacavir
/ lamivudine (doe), Valganciclovir (doe), Sildenafil (doe), Voriconazole (doe) and bosentan (doe), For use by several hospitals dependent on the health service of the principality of asturias.
sulfate and lamivudine tablets in 600 mg and 300 mg doses is a generic bioequivalent of VIV Healthcare's Epzicom tablets, used to treat HIV-1 infection, while olmesartan medoxomil and hydrochlorothiazide tablets, 20 mg/12.
10) Assessing patients' risk for cardiovascular disease is also advised because some data suggest that abacavir
may increase the risk of cardiovascular events, although this remains controversial.
(ABC)-induced liver toxicity is a rare event almost exclusively occurring in HLA B*5701-positive patients, (2) with a handful of cases reported in non carriers of the HLA allele risk.
One meta-analysis of recent observational studies determined that recent abacavir
or protease inhibitor use approximately doubled chances of myocardial infarction.
Groups B and C received an NNRTI, lamivudine, abacavir
, and zidovudine therapy; after week 36, the regimen was reduced to a three-drug NNRTI, lamivudine plus abacavir
in group B and lamivudine, abacavir
plus zidovudine in group C.
Whereas lamivudine tablets may be divided and, if necessary, crushed for easier ingestion by younger children, currently available abacavir
tablets are film-coated and unscored and must be swallowed whole.
Screening for [the HLA-B*5701 gene] markedly reduces the risk of potentially life-threatening hypersensitivity reaction to abacavir
," the guideline authors wrote.
No association of abacavir
use with risk of myocardial infarction or severe cardiovascular disease events: results from ACTG A5001.
Six studies (some not yet published) now have shown increased risk of MI with short-term abacavir
, while three studies found no association between short-term abacavir
and MI risk.
Although certain drugs, for example indinavir, lopinavir, abacavir
and possibly didanosine, are associated with an increased risk of cardiovascular events, the event rates are still lower than that seen in untreated patients and should not be a valid reason for deferring ART.